Effect of oral semaglutide on glucose variability and oxidative stress in type 2 diabetes patients

Effect of oral semaglutide on glucose variability and oxidative stress in type 2 diabetes patients - Effect of oral semaglutide on glucose variability and oxidative stress in type 2 diabetes patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046938

Enrollment

Registered

2022-02-17

Start date

2022-02-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

semaglutide 7mg (maintenance dose reached after 4 weeks of 3 mg semaglutide once daily). Continue DPP-4 inhibitors (regular dose)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a diagnosis of type 2 diabetes mellitus 1) HbA1c 7.0% or more 2) treatment with DPP-4 inhibitors for 12weeks or longer 3) written informed consent 4) 20 years and over

Exclusion criteria

Exclusion criteria: 1)the use of steroids or anti-inflammatory drugs, 2)diabetic ketosis and coma within 3 months before the study, 3)severe infection, severe trauma, pre-and post-operation, 4)an estimated glomerular filtration rate are within 30mL/min/1.73m2, 5)malignancy, 6)pregnancy 7)Patients who are judged as inappropriate for inclusion by phsicians 8)Patients using implantable medical devices such as cardiac pacemakers

Design outcomes

Primary

Measure	Time frame
The primary end point was d-ROMs change from baseline after completing 24 weeks of treatment intervention.	—

Countries

Japan

Contacts

Public ContactMakoto Ohara

Showa University School of Medicine Division of Diabetes and Endocrinology, Department of Internal Medicine

s6018@nms.ac.jp0337848000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026